Restless leg syndrome

Reading File

Finding Sources

Searching PubMed

"restless legs syndrome"[MeSH Terms] AND treatment

Searching Images

restless leg syndrome pathophysiology diagram

Reading File

Finding Sources

Reading File

I now have comprehensive information from multiple authoritative textbooks. Let me compile the full answer.

Restless Leg Syndrome (Willis-Ekbom Disease)

Definition & Epidemiology

Restless Leg Syndrome (RLS) is a neurological sensorimotor disorder characterized by an irresistible urge to move the legs, typically accompanied by uncomfortable sensory disturbances. It is surprisingly common, affecting 3-29% of the general population (prevalence estimates vary by study design). Women are affected more frequently than men. Although incidence increases with age, it can also affect children - in whom it may be confused with "growing pains" or ADHD.

Goldman-Cecil Medicine, p. 453

Clinical Features (Diagnostic Criteria)

Four essential features must be present:

Urge to move the legs - often accompanied by uncomfortable or unpleasant sensations (creeping, crawling, pins and needles, aching, itching, stabbing, heaviness, tension, burning, or coldness)
Worsened by rest/inactivity - especially in the evening with recumbency
Relieved by movement - walking or stretching provides temporary relief (though discomfort returns at rest)
Circadian pattern - worse in the evening and night, peaking between midnight and 4 AM

The sensations are described by patients as "worms," "internal itch," "coldness," or a feeling of heaviness. The relatively proximal location (calves, thighs) distinguishes RLS from acral paresthesias. A small proportion of patients eventually develop similar symptoms in the arms after years of leg symptoms. There are also rare variants involving abdominal restlessness that respond to dopamine agonists.

Adams & Victor's Principles of Neurology, p. 420
Goldman-Cecil Medicine, p. 465

Pathophysiology

Central Iron Dysregulation - Dopamine Hypothesis

The leading mechanism involves central iron dysregulation leading to altered dopaminergic function:

Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis
Iron deficiency leads to decreased dopaminergic modulation of intracortical excitability
Serum ferritin levels are often low in RLS patients even when hemoglobin, hematocrit, and iron-binding capacity are normal
Reduced iron levels have been found in the CSF of RLS patients
PET and SPECT imaging studies have shown decreased dopamine binding by receptors and transporters in the basal ganglia, consistent with dopamine deficiency

Genetics

Primary (idiopathic) RLS is frequently inherited in an autosomal dominant fashion. Eight genetic loci have been identified, including variants in:

MEIS1, BTBD9, MAP2K5/LBXCOR1, PTPRD, PCDHA3
Loci on chromosomes 2p14 and 16q12.1
Goldman-Cecil Medicine, p. 458-460
Adams & Victor's, p. 421

Causes & Associated Conditions

Category	Examples
Primary / Idiopathic	Most cases; autosomal dominant
Iron deficiency	Low ferritin even with normal CBC
Renal failure / Dialysis	Very common (prevalence ~68%); resolves after kidney transplant
Pregnancy	Common especially in 3rd trimester
Peripheral neuropathy	Particularly uremic neuropathy
Drugs	Antidepressants, antihistamines, dopamine antagonists
Thyroid disease	Hypothyroidism
Alcohol	Use before sleep
Neurodegenerative disease	Parkinson disease (higher than chance association)

Adams & Victor's Principles of Neurology, p. 420-421
Bradley and Daroff's Neurology, p. 3723

Relationship to Periodic Leg Movements of Sleep (PLMS)

85-90% of RLS patients also have periodic limb movements in sleep (PLMS)
Only a minority of patients with PLMS meet criteria for RLS
PLMS consists of repetitive movements every 20-90 seconds: dorsiflexion of feet and big toes, sometimes followed by flexion of the hip and knee (resembling the triple-flexion/Babinski response)
PLMS is diagnosed polysomnographically; RLS is diagnosed clinically
PLMS causes microarousals or full arousals, leading to non-restorative sleep

Investigations

In the absence of evidence for a secondary cause, the only routinely indicated test is serum ferritin. If secondary causes are suspected:

Complete blood count (for iron-deficiency anemia)
Renal function tests
Thyroid function tests
Polysomnography (if PLMS needs to be confirmed)

Treatment

Step 1: Treat Underlying Cause

Iron supplementation if ferritin < 75 µg/L (ferrous sulfate 325 mg BID/TID). Also explore the reason for iron deficiency.

Step 2: Pharmacological Therapy

Drug Class	Drug	Dose	Key Risks
Dopamine Agonists (first-line for moderate-severe)	Pramipexole	0.125-0.5 mg, 1.5-2h before bed	Augmentation, impulse control disorders, nausea, hypotension, hallucinations
	Ropinirole	0.25-2 mg, 1.5-2h before bed	Same as above
	Rotigotine patch	1-3 mg/24h	Used when augmentation occurs with oral agents
Alpha-2-delta Ligands (now preferred to avoid augmentation)	Gabapentin encarbil	600-1800 mg/day	Excessive sleepiness, nausea, dizziness
	Gabapentin	300-2700 mg/day	Same
	Pregabalin	25-300 mg/day	Suicidal ideation risk; similar efficacy to pramipexole
Dopamine Precursors	Levodopa/Carbidopa	25/100 mg at bedtime	High augmentation risk; not for chronic use
Benzodiazepines	Clonazepam	0.125-0.5 mg at bedtime	Sedation; caution in sleep apnea
Opioids	Oxycodone, Codeine, Methadone	Various	Addiction, tolerance; for intractable cases
Alpha-2 agonist	Clonidine	0.1 mg BID	Useful if hypertensive; dry mouth, sedation

Bradley and Daroff's Neurology, Table 10.1.11
Goldman-Cecil Medicine, p. 472

Augmentation

Augmentation is the most important complication of dopaminergic therapy - symptoms begin earlier in the day, become more intense, and spread to other body parts. It is more common with levodopa than with dopamine agonists. Management includes:

Switch to rotigotine patch (longer-acting)
Switch to gabapentin/pregabalin (alpha-2-delta ligands)
A clinical trial showed pregabalin was equally effective to pramipexole with lower augmentation rates at the 0.5 mg dose

Special Populations

Renal failure: RLS is extremely common (~68% prevalence). Treatment principles are the same, but iron replacement is particularly important. RLS often persists through dialysis but resolves after kidney transplantation.
Pregnancy: RLS is common in pregnancy; iron supplementation is first-line; dopamine agonists are generally avoided.
Children: May present as "growing pains" or ADHD-like symptoms; iron deficiency is key to check.
Perioperative patients: Iron and ferritin levels should be monitored before and after surgery, especially when significant blood loss is anticipated.

Recent Evidence (2025)

Two significant systematic reviews were published in 2025:

The AASM systematic review and meta-analysis with GRADE assessment (Winkelman et al., JCSM 2025) provides updated evidence-based recommendations for treatment of RLS and periodic limb movement disorder - the most current AASM guidance available.
A systematic review on pharmacological impact on sleep architecture in RLS (Mogavero et al., Sleep Medicine Reviews 2025) analyzed how dopamine agonists, alpha-2-delta ligands, and opioids differently affect polysomnographic measures.
A meta-analysis of tonic motor activation (TOMAC) (Mohamed et al., Sleep Medicine 2025) found this non-pharmacological device-based therapy to be an effective and safe option for RLS - an emerging alternative for patients wishing to avoid long-term dopaminergic augmentation.

Sources: Adams & Victor's Principles of Neurology 12th Ed. | Goldman-Cecil Medicine | Bradley and Daroff's Neurology in Clinical Practice | Goodman & Gilman's Pharmacology

This is a shared conversation. Sign in to Orris to start your own chat.